eLaws | eCases | United States Code | Federal Courts |
Home » Rulemaking » Draft Guidance for Industry onClinical Pharmacogenomics; Availability: Premarketing Evaluation in Early Phase Clinical Studies

Draft Guidance for Industry onClinical Pharmacogenomics; Availability: Premarketing Evaluation in Early Phase Clinical Studies

Document ID: FDA-2011-D-0082-0001
Document Type: Notice
Agency: Food And Drug Administration
Topics: No Topics associated with this document
Federal Register Number: 2011-3679
View Document:  View as format pdf View as format html

Details Information

Document Subtype: NAD-Notice of Availability of Data
Received Date: February 18 2011, at 12:00 AM Eastern Standard Time
Start-End Page: 9583 - 9584
Page Count: 2
Comment Start Date: February 18 2011, at 12:00 AM Eastern Standard Time
Comment Due Date: April 19 2011, at 11:59 PM Eastern Standard Time

Comments

    View All
Total: 14
PhRMA - Comment
Posted: 04/26/2011     ID: FDA-2011-D-0082-0008

Apr 19,2011 11:59 PM ET
Novo Nordisk Inc. - Comment
Posted: 04/06/2011     ID: FDA-2011-D-0082-0004

Apr 19,2011 11:59 PM ET
Boehringer Ingelheim Pharmaceutical, Inc - Comment
Posted: 04/14/2011     ID: FDA-2011-D-0082-0005

Apr 19,2011 11:59 PM ET
American Medical Association (AMA) - Comment
Posted: 04/14/2011     ID: FDA-2011-D-0082-0006

Apr 19,2011 11:59 PM ET
Novartis Pharmaceuticals Corp. - Comment
Posted: 04/14/2011     ID: FDA-2011-D-0082-0007

Apr 19,2011 11:59 PM ET

Related Documents

Total: 0
No documents available.